Patients with metastatic non-small cell lung cancer who are resistant to or relapse after immunotherapy have limited approved treatment options. In a phase 2 trial, Schoenfeld and colleagues administered the centrally manufactured autologous tumor-infiltrating lymphocyte therapy lifileucel to patients who had progression after receiving a median of two prior systemic therapies including anti-PD1/PD-L1 therapy. Six of the 28 patients (21.4%) had an objective response and 19 (79.2%) had a reduction in tumor burden. Responses occurred in tumors with profiles typically resistant to immunotherapy, such as PD-L1–negative, low tumor mutational burden, and STK11 mutation.

See article, p. 1389.

The St. Jude Survivorship Portal is a free, online resource offering in-depth data of over 7,700 long-term childhood cancer survivors. The St. Jude Survivorship Portal includes demographics, diagnoses, cancer treatments, and whole genome sequenced germline genetic data, and a variety of late effects. Users can explore the data through interactive charts, build...

You do not currently have access to this content.